Tempest Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A quorum of 50.7% of voting power was represented. Stockholders approved all four proposals, including two director nominees, auditor ratification, and the proposed equity issuances.
-
Proxies representing 74.3% of outstanding shares established a quorum, but Proposal One lacked sufficient support. The meeting was adjourned to November 12, 2026, for further stockholder consideration.
-
A clinical-stage in vivo CAR-T platform is advancing dual-targeting therapies for cancer and autoimmune diseases, showing strong early efficacy and safety in relapsed multiple myeloma and rare disease patients. New partnerships and rapid development plans position the company as a leader in this emerging field.
Fiscal Year 2024
-
Amezalpat, targeting PPAR-alpha, showed significant efficacy and safety in first-line liver cancer when combined with Tecentriq and Avastin, with benefits across key patient subgroups. A global Phase III trial is set to launch, with additional pipeline progress in renal cancer and FAP syndrome.
-
Positive phase 2 results for amezalpat in liver cancer showed a 35% reduction in risk of death and a six-month survival benefit, with broad FDA support for a phase 3 trial starting next year. The pipeline includes additional assets and expansion plans in other cancers.
-
Amezalpat plus atezolizumab/bevacizumab showed a six-month median OS improvement over standard care in first-line liver cancer, with a hazard ratio of 0.65 and consistent benefit across subgroups. The safety profile was manageable, and a phase III trial is planned with a three-year timeline.
-
A diversified oncology pipeline is advancing, with TPST-1120 showing strong phase II efficacy and safety in first-line liver cancer. A pivotal phase III trial is planned globally, with key OS data and FDA feedback expected soon.